AXIM - AXIM Biotechnologies develops test for biomarker of dry eye disease

AXIM Biotechnologies (OTCQB:AXIM) said it successfully developed a rapid quantitative tear test for matrix metalloproteinase (MMP) MMP-9, an inflammatory biomarker for Dry Eye disease. "Currently available MMP-9 testing does not detect a reduction in tear MMP-9 levels until the concentration drops below 40ng/ml and thus may miss clinically significant improvement that did not reach that threshold," said AXIM’s Chief Medical Officer Joseph Tauber.

For further details see:

AXIM Biotechnologies develops test for biomarker of dry eye disease